Form 4: IRADIMED CEO Sells 5,000 Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, reported the sale of 5,000 shares of common stock on January 5, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, Chairman, and a 10% owner of IRADIMED Corp (IRMD), reported the sale of 5,000 shares of common stock.
• The transactions occurred on January 5, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The sales were conducted in multiple trades at weighted average prices ranging from $95.10 to $99.48 per share.
• Specifically, 854 shares were sold at a weighted average price of $95.10, 300 shares at $95.58, 883 shares at $97.52, 2,209 shares at $98.42, and 754 shares at $99.48.
• Following these transactions, Mr. Susi's indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust decreased to 2,277,500 shares.
• Mr. Susi also indirectly beneficially owns 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust, disclaiming beneficial ownership of the latter except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the execution under a pre-arranged Rule 10b5-1 plan significantly mitigates any negative implications, as it indicates a scheduled transaction rather than a reaction to new, adverse information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were scheduled in advance and not based on new, non-public information, thereby mitigating the negative signal typically associated with insider selling.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a slight reduction in management's direct equity exposure, though the impact is minimal due to the 10b5-1 plan.

Related Party Transactions

• The sales were made from the Phillip Susi 2008 Dynasty Trust, an indirect beneficial ownership vehicle for Roger E. Susi, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sales were pre-planned under a 10b5-1 plan, reducing concerns about management's confidence. The volume of shares sold is also relatively small compared to Mr. Susi's total beneficial ownership.

Key Dates

Recommendation

The reported insider sales by CEO Roger E. Susi are part of a pre-arranged Rule 10b5-1 trading plan, which mitigates the typical negative signal associated with insider selling. These transactions do not reflect a change in the company's fundamentals or a new loss of confidence from management. Therefore, the filing itself does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

IRADIMED, IRMD, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Roger E. Susi, Beneficial Ownership